文献速递膀胱癌与上尿路尿路上皮癌

CT尿路造影与尿细胞学在内镜治疗上尿路尿路上皮癌监测中的作用

CT urography and urinary cytology in surveillance of endoscopically managed UTUC.
PubMed 文献 · BJU Int · 2026-09-28

该多中心回顾性研究评估了CT尿路造影联合尿细胞学能否安全减少内镜保留肾手术后上尿路尿路上皮癌患者的输尿管镜监测。共纳入133例患者、256次输尿管镜评估,结果显示联合检查避免69.2%的输尿管镜但漏诊64.5%的复发,不能安全替代内镜监测;复发率在低危和高危组各随访年保持稳定,支持长期内镜随访。

要点

  • CT联合尿细胞学避免69.2%输尿管镜但漏诊64.5%复发,不能替代内镜监测。
  • 尿细胞学特异性97%但敏感性仅11%,CT敏感性27%、特异性78%。
  • 低危和高危组复发率在各随访年稳定,支持长期内镜随访。

核心结论

  • CT尿路造影和尿细胞学可减少输尿管镜频率,但因漏诊复发率高不能安全替代内镜监测。
  • 内镜保留肾手术后复发率随时间稳定,支持继续长期内镜随访。

研究设计与样本

  • 回顾性多中心分析,纳入2006-2025年两家三级中心接受内镜保留肾手术治疗上尿路尿路上皮癌的患者。
  • 共133例患者和256次输尿管镜评估,监测方案为术后4-6周二次输尿管镜,然后2年内每6个月、之后每年一次。
  • 每次输尿管镜前3个月内行CT尿路造影和尿细胞学,以此为参考标准评估四种触发策略的诊断性能。
  • 分析从第三次输尿管镜开始,采用年化每人年复发率,考虑多次复发并将根治性肾输尿管切除术作为竞争事件。

主要发现

  • 联合CT和/或细胞学敏感性35.5%、特异性75.0%、阳性预测值64.1%(95%CI 52.4-74.7)、阴性预测值48.0%(95%CI 40.4-55.7)。
  • 联合策略避免69.2%的输尿管镜(95%CI 63.1-74.8)但漏诊64.5%的复发(95%CI 56.0-72.4)。
  • 尿细胞学单独特异性97%、敏感性11%;CT单独敏感性27%、特异性78%;两者均阳性特异性近完美但敏感性仅2.8%。
  • 低危组第1-4年复发率分别为0.34、0.35、0.35、0.28事件/人年,高危组分别为0.33、0.38、0.32、0.32事件/人年。

临床怎么用

  • 不应以CT尿路造影联合尿细胞学替代输尿管镜监测,因漏诊复发率高达64.5%。
  • 内镜保留肾手术后需长期内镜随访,因复发率在各随访年保持稳定。

局限性

  • 回顾性多中心设计,样本量133例、256次评估,可能存在选择偏倚。
  • 分析从第三次输尿管镜开始,未评估早期监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to assess whether non-invasive surveillance with computed tomography (CT) urography and urinary cytology could safely reduce the need for ureteroscopy (URS) in patients with upper tract urothelial carcinoma treated with endoscopic kidney-sparing surgery (eKSS). PATIENTS AND METHODS: We performed a retrospective multicentre analysis of patients undergoing eKSS for upper tract urothelial carcinoma at two tertiary centres (2006-2025). Surveillance included second-look URS at 4-6 weeks, then every 6 months for 2 years and annually thereafter. CT urography and urinary cytology were performed within 3 months before each URS, and this served as the reference standard. Four trigger strategies were evaluated for diagnostic performance. Analysis started from the third URS. Recurrence over time was analysed using annualized rates per person-year, accounting for multiple recurrences and treating radical nephroureterectomy as a competing event, overall and by risk group. RESULTS: A total of 133 patients and 256 ureteroscopic assessments were included. Combined CT and/or cytology showed sensitivity of 35.5%, specificity of 75.0%, a positive predictive value of 64.1% (95% confidence interval [CI] 52.4-74.7), and a negative predictive value of 48.0% (95% CI 40.4-55.7), avoiding 69.2% of URS (95% CI 63.1-74.8) but missing 64.5% of recurrences (95% CI 56.0-72.4). Cytology alone was highly specific (97%) but poorly sensitive (11%); CT alone showed moderate sensitivity (27%) and good specificity (78%); requiring both to be positive yielded near-perfect specificity but near-zero sensitivity (2.8%). Recurrence rates were stable across follow-up years at 0.34, 0.35, 0.35, and 0.28 events/person-year at years 1-4 in the low-risk group, and 0.33, 0.38, 0.32, and 0.32 in the high-risk group. CONCLUSIONS: CT urography and urinary cytology may reduce the frequency of URS but cannot safely replace endoscopic surveillance because of the high rate of missed recurrences. Stable recurrence rates over time support the need for continued long-term endoscopic follow-up after eKSS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Scilipoti P, Mura R, Zorzi F, et al. CT urography and urinary cytology in surveillance of endoscopically managed UTUC. BJU Int. 2026. PMID: 42806640. doi:10.1111/bju.70469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。